Surface Oncology (SURF) and The Competition Head-To-Head Contrast
Surface Oncology (NASDAQ: SURF) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Surface Oncology to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.
Earnings and Valuation
This table compares Surface Oncology and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Surface Oncology||$59.42 million||-$6.60 million||-12.64|
|Surface Oncology Competitors||$897.63 million||$190.37 million||-1.33|
This table compares Surface Oncology and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Surface Oncology Competitors||-5,144.22%||-64.24%||-27.96%|
This is a summary of recent ratings and price targets for Surface Oncology and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Surface Oncology Competitors||834||2774||6059||261||2.58|
Surface Oncology presently has a consensus price target of $22.00, indicating a potential upside of 427.58%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.13%. Given Surface Oncology’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Surface Oncology is more favorable than its peers.
Institutional & Insider Ownership
59.8% of Surface Oncology shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Surface Oncology beats its peers on 7 of the 12 factors compared.
About Surface Oncology
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.